Company intelligence / Profile preview
Attune Pharmaceuticals
New York, New York, United Stateskando.tech ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Attune Pharmaceuticals has completed Phase 1 trials for ATN-249, their lead candidate for HAE treatment, demonstrating safety, tolerability, and pharmacodynamic profile. The company raised $23 million in Series B financing to advance ATN-249 through Phase 2 trials.
- Therapeutic areas
- ImmunologyRare Diseases
- Modalities
- Small moleculesOrally-administered therapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Attune Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Attune Pharmaceuticals.